Eisai Co., Ltd. (FRA:EII)

Market Cap	7.48B
Revenue (ttm)	4.63B
Net Income (ttm)	284.33M
Shares Out	n/a
EPS (ttm)	1.01
PE Ratio	26.31
Forward PE	n/a
Dividend	0.95 (3.58%)
Ex-Dividend Date	Sep 29, 2025

Volume	n/a
Average Volume	24
Open	26.52
Previous Close	27.46
Day's Range	26.52 - 26.52
52-Week Range	21.45 - 31.41
Beta	n/a
RSI	57.93
Earnings Date	Feb 9, 2026

About Eisai

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals. The company offers Dayvigo, an orexin receptor antagonist for the treatment of insomnia; LEQEMBI, a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody for Alzheimer’s disease; Lenvima, an orally available multiple receptor tyrosine kinase inhibitor for the treatment of thyroid cancer and hepatocellular carcinoma, thymic carcinoma, renal cell carcinoma, and endometrial carcinoma; Fycompa, an anti-epileptic agent for prim...

• Industry: Pharmaceutical Preparations
• Founded: 1941
• Employees: 10,917
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: EII

Financial Performance

In 2024, Eisai's revenue was 789.40 billion, an increase of 6.42% compared to the previous year's 741.75 billion. Earnings were 46.43 billion, an increase of 9.49%.

Financial numbers in JPY